Bexsero gains propel GSK's vaccines unit to pharma-beating 16% growth in Q1

GlaxoSmithKline grew Bexsero sales 79% in the first quarter to £126 million in the first quarter.

With a new captain at the helm, GlaxoSmithKline maintained its vaccines momentum in the first quarter with 16% growth for the unit, thanks to standout sales from meningitis shots picked up in its Novartis deal. And a new plant and forthcoming launch could keep the growth coming.

Former Novartis vaccines Bexsero and Menveo grew 79% and 17% in the first quarter, respectively, as GSK moves to make the most out of its decision to bet on vaccines. The British drugmaker also reported (PDF) that flu shots Fluarix and FluLaval grew 11% on the period, thanks to early deliveries around the world, and that established vaccines benefited from CDC and wholesaler stocking.

All told, GSK’s vaccines generated £1.15 billion ($1.25 billion) for the drugmaker in the first quarter. The unit’s 16% growth rate outperformed GSK’s first-quarter pharma sales growth of 4% and consumer health’s increase of 2%, all at constant exchange rates.

Virtual Roundtable

ESMO Post Show: Highlights from the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields. Register today.

RELATED: Witty's bet on vaccines pays off in GSK CEO's final full year

Looking forward, GSK execs have several reasons to be optimistic for the future in vaccines. Sensing potential for Bexsero, GSK just last month announced it’s building a $175 million plant in Germany to boost capacity of its star meningococcal B shot.

U.S. and European drug regulators are expected to act on a pipeline vaccine, Shingrix, in the fourth quarter of this year, and so GSK is making moves to ready the launch of a shot expected to reach $1 billion in sales. On the market, the shingles vaccine would take on Merck’s Zostavax.

RELATED: With first Shingrix application, GSK advances toward $1B market duel with Merck

Speaking to analysts on the first-quarter call, new GSK CEO Emma Walmsley said the company’s “immediate focus” is to “deliver excellent commercial execution” on three drug launches, Shingrix included.

She also talked down any remaining hopes that GSK might split, reiterating GSK’s commitment to focus on pharma, vaccines and healthcare. Due to “uncertainty and volatility” in pharma, she said the management team likes “to have more certainty in terms of reliable cash flows both from vaccines and consumer [health]."

RELATED: Glaxo's new chief stands by three-unit structure, foreshadows cultural changes amid 'quiet' Q1 results

Former GSK CEO Andrew Witty bucked the pharma trend back in 2014 when he inked the massive Novartis asset swap, doubling down in low margin business and shipping away pricey cancer meds. In his final year as CEO, the company’s vaccines unit outgrew any other business at the U.K. drug giant.

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.